Protalix BioTherapeutics, Inc. (PLX) Institutional Ownership

Ownership Summary

Protalix BioTherapeutics, Inc. (NYSE:PLX) has 1 institutional investors with active 13F positions as of March 2020.

• These investors held 0.0% of outstanding shares in March 2020, down from 0.0% in December 2019.
• They maintained total shares held in PLX by 0.0% quarter over quarter, and investors in Protalix BioTherapeutics decreased 97.14% from a year ago.
• Activity in PLX broke down as 0 buyers, 0 sellers, and 1 unchanged among 1 total holders.
• The aggregate institutional position in Protalix BioTherapeutics amounted to 0 shares as of March 2020, with no net change quarter on quarter, and down 957.73K shares year over year.
• As of March 31, 2020, the biggest holder of Protalix BioTherapeutics is BlackRock, Inc. at 3.62Mn shares, representing 20.81% of shares outstanding.
• Top purchasers of PLX stock for the quarter ending March 2020 included MAK CAPITAL ONE LLC (3.54Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (432.48K), Prospera Financial Services Inc (418.57K), State Street Corp (387.55K), DIMENSIONAL FUND ADVISORS LP (268.1K).
• The largest sellers of Protalix BioTherapeutics for the quarter ending March 2020 were Opaleye Management Inc. (4.62Mn), Goldman Sachs Group Inc (274.27K), JANE STREET GROUP, LLC (272.58K), COMMONWEALTH EQUITY SERVICES, LLC (152.31K), Round Rock Advisors LLC (118.12K).
• Business Quant data shows the 10 biggest positions in Protalix BioTherapeutics as of March 2020 are held by BlackRock, Inc. (3.62Mn), MAK CAPITAL ONE LLC (3.54Mn), RENAISSANCE TECHNOLOGIES LLC (1.22Mn), State Street Corp (972.82K), Northern Trust Corp (885.45K), GEODE CAPITAL MANAGEMENT, LLC (865.3K), Stratos Wealth Partners, LTD. (500.0K), VANGUARD PORTFOLIO MANAGEMENT LLC (432.48K), Prospera Financial Services Inc (418.57K), Opaleye Management Inc. (340.0K).